I am very excited to serve as track chair for early stage NSCLC and other thoracic tumours at #ESMO24

📆 Abstract closing date is tomorrow! ⏰ 5pm CET

Submit your important work here👇
🔗ow.ly/hyT350RgeC2

Andres Cervantes Rebecca Dent FabriceAndre Solange Peters ESMO - Eur. Oncology

An elegant presentation by Stephen V Liu, MD regarding synergy between immunotherapy and ADCs which could change lung cancer option’s treatment. #InnovativeCancerTherapies #RomeLung24

Had a great time and insightful discussions at #RomeLung24 reviewing biomarkers for #ICI efficacy in #NSCLC . w/ a stellar faculty Jordi Remon Solange Peters Francesco Christian Rolfo, Tony Mok Stephen V Liu, MD, Fred R. Hirsch Federico Cappuzzo Roberto Ferrara Benjamin Besse &…

Dr. Rolf Stahel at #RomeLung24 presents long term survival data with immunotherapy in NSCLC. 5y survival are wonderful to see but lots of room for improvement. About 30% in PDL1 high but only 1% for PDL1 negative.

Dr. Solange Peters at #RomeLung24 with a dynamic discussion of next generation checkpoint inhibitors. Beyond PDL1, many disappointments but the future is bright with novel targets and elegant bispecific antibodies.

Dr. Ross Soo with a glimpse at new immunotherapy agents for NSCLC at #RomeLung24 . Agonists interesting but risk T cell exhaustion. Cytokines remain a challenge. Bispecifics are very encouraging as are new engagers.

Dr. Christian Rolfo discusses the potential role of ctDNA in guiding use of immunotherapy for NSCLC at #RomeLung24 . Monitoring ctDNA dynamics with liquid biopsy may provide escalation strategies and need to be properly integrated into prospective clinical trials.

Dr. Biagio Ricciuti, MD PhD summarizes immunotherapy biomarkers at #RomeLung24 . PDL1 expression is still our best biomarker: higher the better. TMB plays a role but higher cutoffs predict better. STK11/KEAP1 predict poor outcomes with PDL1 but targeting CTLA4 can potentially overcome.

Dr. Jordi Remon at #RomeLung24 discusses cardiotoxicity with immunotherapy - relatively rare in NSCLC, higher in thymus cancers, risk goes up with dual checkpoint blockade. Mainly tachyarrhythmia and myocarditis. But need clearer definitions, consistent baseline assessments.

#RomeLung24

The IASLC #WCLC25 co-chairs are together in Rome…planning, chatting & getting ideas from Federico Cappuzzo

Great to have committed minds pushing each other to ask & answer the important questions

Beaumont RCSI Cancer Centre Noemi Reguart Isabelle Opitz Umberto Malapelle #LCSM

'This is hope.' Jamie L. Studts, PhD gives us the changing narrative.

#HOPESummit24 #redtoque

#RomeLung24

⁦Isabelle Opitz⁩ shares pearls on thoracic surgery decision-making re resectability in locally adv nsclc. Key points:

- imaging could include chest MRI to fully assess resectability
- consider reassessing post induction, as a way forward

⁦OncoAlert⁩ #LCSM

#RomeLung24

Great talk by Fabrice Barlesi on how to advance stage III unresectable nsclc:

- non-oncogene+: additional IO (eg COAST trial)
- oncogene+: novel designs (eg kras, Durva➡️sotorasib in ctDNA+ only), & rarer groups (ALK, ⁦ETOP IBCSG Partners Foundation⁩ BOUNCE)

⁦OncoAlert⁩ #LCsM

#RomeLung24

Neoadjuvant Tsar Tina Cascone reviews the ph III data of neoadj IO in nsclc, highlighting preclinical science that is possible from pre/post neoadj samples that can inform next steps

⁦OncoAlert⁩ ⁦MD Anderson Cancer Center⁩ #LCSM

#RomeLung24

Tony Mok presents key insights on neoadj chemoIO & goes back to basics to chart a path forward:

- which pts don’t benefit? PDL1<1%, KRAS/STK11, non PR
- how do we measure benefit? MPR, pathCR similar
- will MRD refine tx? Platform will matter

@oncoalert #LCSM

#RomeLung24
Superb discussion on future directions for adjuvant IO in nsclc by DOLORES ISLA, important challenges to address:

- long term toxicity of IO
- pt selection by stage + PDL1
- new biomarkers

OncoAlert #LCSM

Dr. Jarushka Naidoo at #RomeLung24 outlines neoadjuvant targeted therapy for resectable NSCLC. Highlights work from Drs. Jackie Aredo Collin Blakely MD, PhD in how neoadjuvant studies can provide insight in persister populations. Many ongoing studies will provide more valuable data!

#RomeLung24 - Dr. Naidoo Jarushka Naidoo on stage in Rome discussing on perioperative strategies with targeted therapies in NSCLC: there remains many open questions duration of treatment, optimal endpoints, role of ChT…New SoC coming soon in EGFR+ LA disease #ASCO24

#RomeLung24
Prof Yi Long Wu summarizes many yrs of data exploring adjuvant TKI in EGFR+ nsclc, next questions:

- do pts need adj chemo re TKI (adaura)?
- can we move to precision adjuvant therapy, RB1 alterations may identify a high risk group

@Oncoalert #LCSM

Taking in some of the local flavor at #RomeLung24 - ready for some great talks tomorrow! Federico Cappuzzo Marina Garassino JessicaJLinMD Christian Rolfo ProfSiowMingLee Fred R. Hirsch Jarushka Naidoo Hossein Borghaei, DO